Ross Laman
A5058856431- Glioma Diagnosis and Treatment
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
- Circular RNAs in diseases
- Epigenetics and DNA Methylation
- BRCA gene mutations in cancer
- Genetic factors in colorectal cancer
- Testicular diseases and treatments
- DNA Repair Mechanisms
- Multiple Myeloma Research and Treatments
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Lung Cancer Treatments and Mutations
Wellcome Sanger Institute
2005-2006
Abstract Protein kinases are frequently mutated in human cancer and inhibitors of mutant protein have proven to be effective anticancer drugs. We screened the coding sequences 518 (∼1.3 Mb DNA per sample) for somatic mutations 26 primary lung neoplasms seven cell lines. One hundred eighty-eight were detected 141 genes. Of these, 35 synonymous (silent) changes. This result indicates that most 188 “passenger” not causally implicated oncogenesis. However, an excess ∼40 nonsynonymous...
Abstract Malignant gliomas have a very poor prognosis. The current standard of care for these cancers consists extended adjuvant treatment with the alkylating agent temozolomide after surgical resection and radiotherapy. Although statistically significant increase in survival has been reported this regimen, nearly all recur become insensitive to further class agents. We sequenced 500 kb genomic DNA corresponding kinase domains 518 protein kinases each nine gliomas. Large numbers somatic...
Abstract The protein kinase gene family is the most frequently mutated in human cancer. Previous work has documented activating mutations KIT receptor tyrosine testicular germ‐cell tumors (TGCT). To investigate further potential role of kinases development TGCT and to characterize prevalence patterns point these tumors, we have sequenced coding exons splice junctions annotated 518 genes a series seven seminomas six nonseminomas. Our results show remarkably low mutation frequency, with only...
Supplementary Glioma Gene Mutations from A Hypermutation Phenotype and Somatic <i>MSH6</i> in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy
<div>Abstract<p>Malignant gliomas have a very poor prognosis. The current standard of care for these cancers consists extended adjuvant treatment with the alkylating agent temozolomide after surgical resection and radiotherapy. Although statistically significant increase in survival has been reported this regimen, nearly all recur become insensitive to further class agents. We sequenced 500 kb genomic DNA corresponding kinase domains 518 protein kinases each nine gliomas. Large...
Supplementary Glioma Genes from A Hypermutation Phenotype and Somatic <i>MSH6</i> Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy
Supplementary Glioma Genes from A Hypermutation Phenotype and Somatic <i>MSH6</i> Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy
Supplementary Information from A Hypermutation Phenotype and Somatic <i>MSH6</i> Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy
Supplementary Information from A Hypermutation Phenotype and Somatic <i>MSH6</i> Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy
<div>Abstract<p>Malignant gliomas have a very poor prognosis. The current standard of care for these cancers consists extended adjuvant treatment with the alkylating agent temozolomide after surgical resection and radiotherapy. Although statistically significant increase in survival has been reported this regimen, nearly all recur become insensitive to further class agents. We sequenced 500 kb genomic DNA corresponding kinase domains 518 protein kinases each nine gliomas. Large...
Supplementary Glioma Gene Mutations from A Hypermutation Phenotype and Somatic <i>MSH6</i> in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy